GI Innovation
GI Innovation is a South Korea-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific fusion proteins GI-101, GI-102 and GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma.
Overview
GI Innovation is a South Korean biotechnology company developing bispecific fusion protein drugs on its GI-SMART platform for immuno-oncology and allergy. Its lead cancer candidates are GI-101 and GI-102 (CD80 and IL-2 variant fusion proteins) and GI-108 (anti-CD73 with an IL-2 variant), in phase 1/2 trials in Korea, the United States and Australia. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07172802 (phase 1/2, A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy...), NCT05824975 (phase 1/2, A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and...) and NCT04977453 (phase 1/2, GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +42
- targets +12
- modalities +8
- regions +7
- 24-month regulatory events +10
- registry trials +30
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
A sea-sponge-derived chemotherapy that extended survival in heavily pretreated breast cancer and in liposarcoma, where almost nothing else had.
Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
An oral anti-angiogenic pill that matched sorafenib in liver cancer with higher response rates, and partners with pembrolizumab in kidney and endometrial cancer.
Similar pages
not linked directly; found by shared links- TrialGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Melanoma, Small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Pembrolizumab, Pancreatic ductal adenocarcinoma.
- TrialStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Shares Trastuzumab deruxtecan, Paclitaxel / nab-paclitaxel, Ovarian cancer, Small-cell lung cancer.
- TrialSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Shares Paclitaxel / nab-paclitaxel, Cervical cancer, Head and neck squamous cell carcinoma, Melanoma.
- TrialPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Shares Lenvatinib, Renal cell carcinoma, Hepatocellular carcinoma, Small-cell lung cancer.
- TrialA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Shares Lenvatinib, Doxorubicin, Hepatocellular carcinoma, Colorectal cancer.
- TrialA Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Melanoma, Small-cell lung cancer, Pembrolizumab.
- TrialA Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.